NGcGM3/VSSP vaccine as treatment for melanoma patients

References

• Potapenko M, Shurin GV, de León J. Gangliosides as immunomodulators. Adv Exp Med Biol 2007; 601:195 - 203; http://dx.doi.org/10.1007/978-0-387-72005-0_20; PMID: 17713006
   PubMed Web of Science ®Google Scholar
• Carr A, Mullet A, Mazorra Z, Vázquez AM, Alfonso M, Mesa C, et al. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 2000; 19:241 - 7; http://dx.doi.org/10.1089/02724570050109639; PMID: 10952412
   PubMed Web of Science ®Google Scholar
• Stults CLM, Sweeley CC, Macher BA. Glycosphingolipids: structure, biological source, and properties. Methods Enzymol 1989; 179:167 - 214; http://dx.doi.org/10.1016/0076-6879(89)79122-9; PMID: 2695766
   PubMed Web of Science ®Google Scholar
• Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 1996; 56:5309 - 18; PMID: 8968075
   PubMed Web of Science ®Google Scholar
• Portoukalian J, Zwingelstein G, Doré JF. Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur J Biochem 1979; 94:19 - 23; http://dx.doi.org/10.1111/j.1432-1033.1979.tb12866.x; PMID: 436839
   PubMedGoogle Scholar
• Fernández LE, Gabri MR, Guthmann MD, Gómez RE, Gold S, Fainboim L, et al. NGcGM3 ganglioside: a privileged target for cancer vaccines. Clin Dev Immunol 2010; 2010:814397; http://dx.doi.org/10.1155/2010/814397; PMID: 21048926
   PubMed Web of Science ®Google Scholar
• Roque-Navarro L, Chakrabandhu K, de León J, Rodríguez S, Toledo C, Carr A, et al. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol Cancer Ther 2008; 7:2033 - 41; http://dx.doi.org/10.1158/1535-7163.MCT-08-0222; PMID: 18645013
   PubMed Web of Science ®Google Scholar
• de León J, Fernández A, Clavell M, Labrada M, Bebelagua Y, Mesa C, et al. Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25- effector and naturally occurring CD4+CD25+ regulatory T cells function. Int Immunol 2008; 20:591 - 600; http://dx.doi.org/10.1093/intimm/dxn018; PMID: 18310617
   PubMed Web of Science ®Google Scholar
• Labrada M, Clavell M, Bebelagua Y, León Jd, Alonso DF, Gabri MR, et al. Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy. Expert Opin Biol Ther 2010; 10:153 - 62; http://dx.doi.org/10.1517/14712590903443084; PMID: 20088712
   PubMed Web of Science ®Google Scholar
• Birklé S, Zeng G, Gao L, Yu RK, Aubry J. Role of tumor-associated gangliosides in cancer progression. Biochimie 2003; 85:455 - 63; http://dx.doi.org/10.1016/S0300-9084(03)00006-3; PMID: 12770784
   PubMed Web of Science ®Google Scholar
• Deng W, Li R, Ladisch S. Influence of cellular ganglioside depletion on tumor formation. J Natl Cancer Inst 2000; 92:912 - 7; http://dx.doi.org/10.1093/jnci/92.11.912; PMID: 10841826
   PubMed Web of Science ®Google Scholar
• Hayashi N, Chiba H, Kuronuma K, Go S, Hasegawa Y, Takahashi M, et al. Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody. Cancer Sci 2013; 104:43 - 7; http://dx.doi.org/10.1111/cas.12027; PMID: 23004020
   PubMed Web of Science ®Google Scholar
• Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, et al. Gangliosides expressed in human breast cancer. Cancer Res 1996; 56:5165 - 71; PMID: 8912852
   PubMed Web of Science ®Google Scholar
• Oliva JP, Valdés Z, Casacó A, Pimentel G, González J, Alvarez I, et al. Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc. Breast Cancer Res Treat 2006; 96:115 - 21; http://dx.doi.org/10.1007/s10549-005-9064-0; PMID: 16322892
   PubMed Web of Science ®Google Scholar
• Blanco R, Cedeño M, Escobar X, Blanco D, Rengifo Ch, Frómeta M, et al. Immunorecognition of the 14F7 Mabraised against N-Glycolyl GM3 Ganglioside in some normal and malignant tissues from genitourinary system. ISRN Pathology 2011; Article ID 953803, 10 pages.
   Google Scholar
• Scursoni AM, Galluzzo L, Camarero S, Lopez J, Lubieniecki F, Sampor C, et al. Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer. Clin Dev Immunol 2011; 2011:245181; http://dx.doi.org/10.1155/2011/245181; PMID: 21941577
   PubMed Web of Science ®Google Scholar
• Blanco R, Rengifo E, Cedeño M, Rengifo CE, Alonso DF, Carr A. Immunoreactivity of the 14F7 MAb raised against N-Glycolyl GM3 ganglioside in epithelial malignant tumors from digestive system. ISRN Gastroenterol 2011; 2011:645641; http://dx.doi.org/10.5402/2011/645641; PMID: 21991524
   PubMedGoogle Scholar
• Estevez F, Carr A, Solorzano L, Valiente O, Mesa C, Barroso O, et al. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine 1999; 18:190 - 7; http://dx.doi.org/10.1016/S0264-410X(99)00219-4; PMID: 10501249
   PubMed Web of Science ®Google Scholar
• Blanco R, Rengifo E, Rengifo Ch, Cedeño M, Frómeta M, Carr A. immunohistochemical reactivity of the 14F7 monoclonal antibody raised against N-Glycolyl GM3 Ganglioside in some bening and malignant skin neoplasms. Dermatology 2011; Article ID 848909, 8 pages.
   Google Scholar
• Osorio M, Gracia E, Rodríguez E, Saurez G, Arango MdelC, Noris E, et al. Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study. Cancer Biol Ther 2008; 7:488 - 95; http://dx.doi.org/10.4161/cbt.7.4.5476; PMID: 18285705
   PubMed Web of Science ®Google Scholar
• Osorio M, Gracia E, Reigosa E, Hernandez J, de la Torre A, Saurez G, et al. Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma. Cancer Manag Res 2012; 4:341 - 5; http://dx.doi.org/10.2147/CMAR.S22617; PMID: 23055778
   PubMedGoogle Scholar